Skip to content
value.today

Serina Therapeutics, Inc.

SER
$50 Mmarket cap on Oct 30, 2026
Compare
World rank
#21,260
Revenue
$0 M
For year ending December-2025
Net income
$-19 M
-14753.8% margin
SEC filing
Employees
16
As of December 31, 2025
SEC filing

Serina Therapeutics, Inc. in brief

Serina Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Huntsville, Alabama, USA. Its market value was $50 M on 30 October 2026, which makes it the 21,260th largest listed company in the world and the 3,852nd largest in the USA on this site. In the year to December 2025 it had sales of $0 M and a net loss of $19 M. It employs about 16 people. Its largest product and service lines by sales in 2025 were Grant revenues (100%). Its shares trade under the symbol SER (NYSE).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Serina Therapeutics, Inc.

We are a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and other indications. Our POZ drug delivery technology is designed to enable certain existing drugs and novel drug candidates to be modified in a way that provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs).The Company’s proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline) and is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via easy-to-administer, long-acting subcutaneous injection.

From the company's annual report filed with the US SEC: read the report

Serina Therapeutics, Inc. timeline

3 events, 2017–2024
  1. 2017
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2023
  4. 💰
    Record revenue of $3 million
    FY2023, the highest of the 8 years on record.
  5. 2024
  6. ✎
    Renamed Serina Therapeutics, Inc.
    Formerly AgeX Therapeutics, Inc..

Events of Serina Therapeutics, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$14 M$27 M$41 M$54 M

World rank over time

▲ up 174 places since 2026
2026-10-14: #21471#21,47120262026-10-30: #21297#21,2972026

Rank in USA: #3,855 (Oct 2026) · #3,856 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
386.3×
Price / book
—
Free cash flow yield
-35.9%
Net margin
-14753.8%
Operating margin
-18476.9%
Return on equity
—
Liabilities / assets
100.6%
Net debt
$17M
Revenue growth
+116.7%
R&D / revenue
10123.1%
Revenue per employee
$8 K
Profit per employee
$-1.2 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $1M, net income $-8M$1MFY18Fiscal year ending Dec 2019: revenue $2M, net income $-12M$2MFY19Fiscal year ending Dec 2020: revenue $0M, net income $-11M$0MFY20Fiscal year ending Dec 2021: revenue $0M, net income $-9M$0MFY21Fiscal year ending Dec 2022: revenue $0M, net income $-10M$0MFY22Fiscal year ending Dec 2023: revenue $3M, net income $5M$3MFY23Fiscal year ending Dec 2024: revenue $0M, net income $-11M$0MFY24Fiscal year ending Dec 2025: revenue $0M, net income $-19M$0MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$0M+116.7%$-24M$-19M-14753.8%
Dec 2024$0M-98.1%$-17M$-11M-18566.7%
Dec 2023$3M+10400.0%$-3M$5M167.3%
Dec 2022$0M-78.6%$-7M$-10M-34866.7%
Dec 2021$0M-61.1%$-8M$-9M-6200.0%
Dec 2020$0M-79.2%$-10M$-11M-3016.7%
Dec 2019$2M+23.6%$-13M$-12M-702.3%
Dec 2018$1M—$-11M$-8M-535.7%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-18M$0M$-18M$-1.91—
Dec 2024$-17M$0M$-17M$-1.51—
Dec 2023$-2M$1M$-3M$0.73—
Dec 2022$-6M——$-9.70—
Dec 2021$-8M——$-0.23—
Dec 2020$-8M$0M$-8M$-0.29—
Dec 2019$-10M$1M$-11M$-0.33—
Dec 2018$-8M$0M$-8M$-0.21—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-3M—Dec ’24Three months to Mar 2025: revenue —, net income $-5M—Mar ’25Three months to Jun 2025: revenue $0M, net income $-6M$0MJun ’25Three months to Sep 2025: revenue —, net income $-5M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-3M—Dec ’25Three months to Mar 2026: revenue —, net income $-7M—Mar ’26Three months to Jun 2026: revenue —, net income $-6M—Jun ’26Three months to Sep 2026: revenue $0M, net income $-8M$0MSep ’26

Latest quarter to Sep 2026: revenue $0M, net income $-8M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Serina Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$0 M
Operating income
$-24 M
Net income
$-19 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$7 M
Total liabilities
$7 M
Total equity
$-0 M

As of December-2025

Top 28 institutional investors in Serina Therapeutics, Inc.#

As of Sep 30, 2026
28 institutions held 2.5 M shares (about 9.4% of the shares outstanding) on Sep 30, 2026. The ten largest hold 9.3%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Serina Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Sio Capital Management, LLC2,000,000+1,000,000 (+100.00%)7.53%$4 MNov 16, 2026
2Vanguard Capital Management LLC184,703+22,505 (+13.88%)0.70%$0 MNov 13, 2026
3Ashton Thomas Private Wealth, LLC88,888New0.33%$0 MNov 3, 2026
4Waverly Advisors, LLC67,4920 (0.00%)0.25%$0 MNov 16, 2026
5Geode Capital Management, LLC32,203-18,804 (-36.87%)0.12%$0 MNov 6, 2026
6Virtu Financial LLC22,596New0.09%$0 MNov 17, 2026
7Northern Trust Corp20,7710 (0.00%)0.08%$0 MNov 16, 2026
8Vanguard Fiduciary Trust Co20,0090 (0.00%)0.08%$0 MNov 13, 2026
9Avidian Wealth Enterprises, LLC18,8000 (0.00%)0.07%$0 MOct 8, 2026
10State Street Corp12,7580 (0.00%)0.05%$0 MNov 12, 2026
11Keel Point, LLC10,809-10,699 (-49.74%)0.04%$0 MNov 16, 2026
12Citigroup Inc5,230New0.02%$0 MNov 4, 2026
13Caitong International Asset Management Co., Ltd3,682-62 (-1.66%)0.01%$0 MOct 29, 2026
14Wells Fargo & Company/mn3,6110 (0.00%)0.01%$0 MNov 16, 2026
15Tower Research Capital LLC (TRC)3,075+505 (+19.65%)0.01%$0 MNov 16, 2026
16BlackRock, Inc.2,3780 (0.00%)0.01%$0 MNov 13, 2026
17Osaic Holdings, Inc.2,0020 (0.00%)0.01%$0 MNov 12, 2026
18Royal Bank Of Canada1,000New0.00%$0 MNov 16, 2026
19Morgan Stanley608+594 (+4242.86%)0.00%$0 MNov 13, 2026
20Piscataqua Savings Bank280 (0.00%)0.00%$0 MOct 21, 2026
21Albion Financial Group /ut80 (0.00%)0.00%$0 MOct 21, 2026
22Pacifica Partners Inc.80 (0.00%)0.00%$0 MOct 9, 2026
23UBS Group AG5-1,342 (-99.63%)0.00%$0 MNov 10, 2026
24Barclays PLC4-541 (-99.27%)0.00%$0 MNov 6, 2026
25Jpmorgan Chase & Co3+2 (+200.00%)0.00%$0 MNov 12, 2026
Show all 28: investors 26 to 28
Institutional investors 26 to 28 in Serina Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26BNP Paribas Financial Markets20 (0.00%)0.00%$0 MNov 12, 2026
27Rockefeller Capital Management L.P.20 (0.00%)0.00%$0 MNov 13, 2026
28Farther Finance Advisors, LLC10 (0.00%)0.00%$0 MOct 8, 2026

Mutual funds holding Serina Therapeutics, Inc.#

6 funds hold shares worth $0 M (about 0.8% of the company). Since their previous reports 1 added shares and 2 sold.
Mutual funds holding Serina Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.125,805$0 M0.47%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC45,248$0 M0.17%<0.01%+56%May 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.33,331$0 M0.13%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC4,739$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC2,592$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC2,495$0 M<0.01%<0.01%no changeJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 6 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Serina Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$78 K
7 purchases, 4 insiders
Sold, 12 months
$335 K
21 sales, 1 insider
Net, 12 months
-$257 K
open market only
Insiders on file
10
since
$313 K-$411 K$0May 2024: bought $313 K (13 trades), sold $0 (0 trades)May 24Jun 2024: bought $71 K (2 trades), sold $0 (0 trades)Aug 2024: bought $259 K (10 trades), sold $0 (0 trades)Sep 2024: bought $134 K (4 trades), sold $0 (0 trades)SepDec 2024: bought $18 K (1 trades), sold $0 (0 trades)Jun 2025: bought $0 (0 trades), sold $38 K (1 trades)Jul 2025: bought $0 (0 trades), sold $170 K (5 trades)JulAug 2025: bought $0 (0 trades), sold $411 K (6 trades)Oct 2025: bought $0 (0 trades), sold $87 K (4 trades)Nov 2025: bought $0 (0 trades), sold $104 K (6 trades)NovDec 2025: bought $0 (0 trades), sold $80 K (9 trades)Jan 2026: bought $0 (0 trades), sold $94 K (7 trades)Feb 2026: bought $0 (0 trades), sold $20 K (1 trades)FebMar 2026: bought $0 (0 trades), sold $116 K (2 trades)May 2026: bought $58 K (4 trades), sold $0 (0 trades)Jun 2026: bought $18 K (2 trades), sold $0 (0 trades)JunJul 2026: bought $2 K (1 trades), sold $0 (0 trades)
Bought (open market)Sold (open market)Hover a month for the totals
Serina Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Stephen K. BrannanDirectorBuy+1,000$2.030$2 K1,000Form 4
filed Gregory BaileyDirectorConversion+1.77 M$2.250$4.0 M1.90 MForm 4
filed Gregory BaileyDirectorConversion+6.67 M$2.250$15.0 M8.56 MForm 4
filed Jay VenkatesanDirectorConversionindirect+224,152$2.250$504 K231,705Form 4
filed Karen J. WilsonDirectorBuy+5,000$1.770$9 K10,100Form 4
filed Karen J. WilsonDirectorBuy+5,100$1.750$9 K5,100Form 4
filed Steven A. LedgerChief Executive Officer, DirectorGrant or award+10,100$1.930$19 K10,100Form 4
filed Jay VenkatesanDirectorBuy+589$1.780$1 K589Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Serina Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
46,787
0.4% of shares · 1 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-35.17 reverse split in the period to ; 1-for-35.21 reverse split

Trading halts

  • 2025-09-09 19:12 UTC, code T3, resumed 20:00 UTC
  • 2025-08-26 13:36 UTC, code M, resumed 13:41 UTC

Fails to deliver

  • : 2,116 shares at $1.89
  • : 44 shares at $1.64
  • : 163 shares at $1.67
  • : 4,994 shares at $1.71
  • : 202 shares at $1.72

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Serina Therapeutics, Inc. scorecard#

Passes 1 of the 14 checks that could be worked out: strongest in financial health (1 of 3), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation0 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
    • ✗Price to sales below its peers' median386.3×Price to sales 386.3× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-35.9%Free cash flow is -35.9% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 3
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-1.91 vs -1.51Diluted EPS -1.91 in fiscal 2025 against -1.51 the year before (report's currency).
    • ✗Net income higher than five years earlier-$19 M-$19 M in fiscal 2025 against -$11 M in 2020.
    • ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$19 MNet income -$19 M in fiscal 2025.
    • ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities1.7×Current ratio 1.71 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-19.43Z-score -19.43 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year38.5%Diluted shares up 38.5% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Serina Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Serina Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017
Income statement
Revenue0.10.13.2r0.00.10.4r1.71.41.4
Cost of revenue——0.00.00.00.0r0.20.40.2
Gross profit——0.10.00.10.3r1.51.01.2
Research and development137.52.4r1.01.53.7r5.95.85.8
General and administrative119.63.9r6.06.76.7r8.15.63.9
Operating expenses24176.3r7.08.210r14r−12r9.7
Operating income−24−17−3.1r−7.0−7.9−10r−13−11−6.7
Interest expense and finance costs0.20.54.93.31.1————
Other non-operating income (expense)4.85.88.4r−3.5−0.6−0.3r0.33.50.0
Income before tax−19−11r5.3r118.7r−11−12−7.7—
Income tax0.000——−0.20.1——
Income from continuing operations———−10−8.6−10———
Income from discontinued operations————−0.1−0.7———
Net income including minority interests−19−115.3r−11−8.7−11−12−7.7−6.6
Minority interests' share of net income−0.0−0.10r−0.1−0.0−0.1−0.2−0.2−0.1
Net income attributable to shareholders−19−115.3r−10−8.7−11−12−7.5−6.6
Earnings per share, basic-1.91-1.512.36r-9.70r-0.23-0.29-0.33-0.21-0.21
Earnings per share, diluted-1.91-1.510.73r-9.70-0.23-0.29-0.33-0.21-0.21
Shares, weighted average (basic)107.42.2r0.0r38————
Shares, weighted average (diluted)107.47.4r0.03838373531
Balance sheet
Cash and cash equivalents3.13.77.6r0.60.60.52.46.77.4
Receivables——0.10.00.00.30.40.10.1
Other current assets0.30.10r1.81.61.41.31.00.1
Current assets6.15.77.6r2.52.22.34.17.97.6
Property, plant and equipment0.50.50.6———1.10.10.1
Right-of-use (leased) assets0.40.50.7———0.7——
Other intangible assets——0r0.70.91.62.22.71.9
Total assets7.06.79.0r3.23.23.97.4119.6
Accounts payable1.90.70.6r0.60.20.80.40.20.1
Current liabilities3.62.41.4r109.05.43.32.4—
Lease liabilities (non-current)0.20.30.5——————
Total liabilities7.06.24.9r21159.34.82.41.3
Retained earnings−64−44−33r−116−106−97−86−74−67
Shareholders' equity−0.00.6−32r−38r−12−5.12.27.47.3
Minority interests0−0.10r−0.1−0.0−0.30.40.81.0
Total equity−0.00.5−32r−38r−12−5.42.68.28.3
Total liabilities and equity7.06.79.0r3.23.23.97.4119.6
Shares outstanding119.42.4r1.1r3838r383634
Cash-flow statement
Depreciation and amortization0.10.1r0.1——0.7r0.40.1—
Share-based compensation3.82.60.0r0.81.00.9r1.91.30.1
Cash from operating activities−18−17−2.5r−5.9−7.9−7.8−10−8.0−6.3
Capital expenditure−0.1−0.0−0.5——−0.0−0.6−0.0−0.0
Cash from investing activities−0.1−0.0−0.5r—0.7−0.0−0.41.30.0
Debt issued—————0.4———
Shares issued————0.5——5.010
Cash from financing activities171310r6.07.26.06.36.013
Exchange-rate effect on cash————————0.1
Change in cash−0.6−3.97.1r0.10.1−1.9−4.3−0.77.1
Report10-K10-K10-K10-K10-K10-K10-K10-K/A10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Serina Therapeutics, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Grant revenues$0 M100%

Business segments

  • Reportable$0 M100%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Executive pay at Serina Therapeutics, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$638 K
Other top executives, average
$545 K
the CEO earned 1.2× this
$100 invested is now
$10
Serina Therapeutics, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Chief executive$638 K−$357 K$545 K$10
2024Chief executive$3.7 M$3.7 M$1.7 M$25
2023Chief executive$1.1 M$1.1 M$300 K$70

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Serina Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling

Delisting notice 1 · Directors and officers 5 · Material agreement 4 · New debt 1 · Unregistered share sale 3 · Bylaws or fiscal year changed 6 · Shareholder vote 2 · Results announced 7

Serina Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Bylaws or fiscal year changed8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Bylaws or fiscal year changedShareholder vote8-K
Results announced8-K
Directors and officersBylaws or fiscal year changed8-K
Results announced8-K
Directors and officersMaterial agreementUnregistered share saleBylaws or fiscal year changed8-K
Delisting notice8-K
Results announced8-K
Shareholder vote8-K
Material agreementNew debtUnregistered share sale8-K
Bylaws or fiscal year changed8-K
Results announced8-K
Directors and officersBylaws or fiscal year changed8-K
Results announced8-K
Material agreement8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

3 private funding rounds before listing

Private share sales · funding history

Private share sales of Serina Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2019$5 MNo. 3$2 to $10 million17equitySEC
Jun 2018$5 MNo. 2$2 to $10 million1equitySEC
Jun 2017$9 MNo. 1$2 to $10 million18equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Serina Therapeutics, Inc.#

$0 spent on lobbying the US Congress and federal agencies in 2020.

Lobbying, 2020
$0
#1,392 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2020
2026 so far
—

Lobbying firms hired in 2020

Bradley Arant Boult Cummings LLP

Serina Therapeutics, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2020$0—3
2019$0—4
2018$60 K—4

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Serina Therapeutics, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

Layoffs at Serina Therapeutics, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
12
2020–2020
Latest
12 people
2020-04-24
Serina Therapeutics, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2020···12········12
Serina Therapeutics, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
12 peopleRestructuring planSEC 8-K“The reduction in staffing is anticipated to affect 12 employees, primarily research and development personnel, and is expected to be completed on or around May 1, 2020.”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Serina Therapeutics, Inc. compares in Biotechnology

  • Market cap$50 M · higher than 26% of 726
  • Revenue$0 M · higher than 17% of 647
  • Revenue growth116.7% · higher than 84% of 438
  • Price / sales386.3× · lower than 3% of 339
  • FCF yield-35.9% · higher than 31% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Serina Therapeutics, Inc.🇺🇸$50 M——+116.7%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Serina Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Serina Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Serina Therapeutics, Inc.? Suggest a correction